Company intelligence / Profile preview
Machavert Pharmaceuticals
Aurora, Colorado, United Statesmachavert.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Machavert is developing small molecule RAL GTPase inhibitors aimed at controlling the growth and metastasis of KRAS mutant cancers. The company is in preclinical stage, conducting lead optimization and efficacy testing in preparation for IND enabling studies.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
University of Colorado
Beyond the preview
Go deeper on Machavert Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Machavert Pharmaceuticals.